The study, published in NPJ Vaccines, tested the vaccine on mice and monkeys with positive results. The vaccine lowers LDL cholesterol almost as effectively as PCSK9 inhibitors, according to a Dec. 14 system news release. It has been tested over the past decade on monkeys and mice with “promising results,” the release said
“The vaccine is based on a non-infectious virus particle,” lead author Bryce Chackerian, PhD, a professor in the molecular genetics and microbiology department at the university, said in the release. “It is just the shell of a virus, and it turns out that we can use that shell of a virus to develop vaccines against all sorts of different things.”
The vaccine could be cheaper than $100 per dose.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
